Related Experiment Video
Updated: Apr 9, 2026
Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
Published on: January 21, 2018
In Vitro Treatment with 2-APB Inhibits the Inflammation in Nasal Polyps
Lin Lin1, Fei Dai2, Zhongchun Chen2
1Department of Otorhinolaryngology-Head and Neck Surgery, Huashan Hospital of Fudan University, Shanghai, China linlinhsn@aliyun.com.
Objective:
Glucocorticoids are considered the main treatment option for chronic rhinosinusitis with nasal polyps (CRSwNP), but their effect rate ranges from 60.9% to 80%. Novel therapeutic means should be studied. The purpose of this study was to investigate the expression of Orai1 in nasal polyps (NPs) and the influence of intervention of Orai1 on NPs after in vitro treatment of 2-aminoethoxydiphenyl borate (2-APB).
Study Design:
Prospective cross-sectional study.
Setting:
University hospital.
Subjects And Methods:
Nasal biopsy samples were obtained from normal subjects or subjects with CRSwNP. We studied the localization of Orai1 protein in NPs by using immunohistochemistry. Then these tissues in cultures were maintained in the absence or presence of dexamethasone (DEX) or 2-APB. Orai1 was examined by Western blot, enzyme-linked immunosorbent assay (ELISA), and real-time reverse transcription-polymerase chain reaction (RT-PCR). Inflammatory mediators including interleukin (IL)-1β, IL-5, eosinophil cation protein (ECP), leukotriene (LT)C4, interferon (IFN)-γ, and dermatophagoides pteronyssinus (DP)-specific immunoglobulin E (sIgE) as well as mucins (MUCs) including MUC5B and MUC7 in cultures were analyzed with ELISA and real-time RT-PCR.
Results:
The expression of Orai1 was localized to cytoplasmic membrane of inflammatory cells and submucosal glandular cells and was upregulated in NPs compared with normal nasal mucosa. Orai1 was decreased in NPs after in vitro treatment of 2-APB but not after DEX intervention. The levels of inflammatory mediators and mucins were reduced more after 2-APB treatment when compared with those after DEX treatment.
Conclusion:
Orai1 may play crucial roles in NP formation, and the intervention of Orai1 may inhibit NP development.
Insights
Investigating Orai1 in nasal polyps (NPs) revealed its upregulation. Inhibiting Orai1 with 2-aminoethoxydiphenyl borate (2-APB) reduced inflammatory mediators and mucins, suggesting Orai1 intervention may hinder NP development.
Area of Science:
- Otorhinolaryngology
- Immunology
- Molecular Biology
Background:
- Glucocorticoids are the primary treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), but their efficacy is limited (60.9%-80%).
- Novel therapeutic targets are needed for CRSwNP management.
- Orai1, a calcium channel, is implicated in inflammatory processes.
Purpose of the Study:
- To investigate Orai1 expression in nasal polyps (NPs).
- To determine the effect of 2-aminoethoxydiphenyl borate (2-APB), an Orai1 inhibitor, on NPs in vitro.
- To compare the efficacy of Orai1 intervention with dexamethasone (DEX) in CRSwNP models.
Main Methods:
- Prospective cross-sectional study at a university hospital.
- Nasal biopsy samples from CRSwNP patients and normal subjects.
- Immunohistochemistry, Western blot, ELISA, and RT-PCR to analyze Orai1 expression.
- In vitro treatment with DEX or 2-APB, followed by analysis of inflammatory mediators and mucins.
Main Results:
- Orai1 expression was upregulated in NPs compared to normal nasal mucosa, localized to inflammatory and glandular cells.
- 2-APB treatment significantly decreased Orai1 expression in NPs, while DEX did not.
- 2-APB treatment resulted in greater reduction of inflammatory mediators (IL-1β, IL-5, ECP, LTC4, IFN-γ, sIgE) and mucins (MUC5B, MUC7) than DEX treatment.
Conclusions:
- Orai1 plays a significant role in the formation and development of nasal polyps.
- Intervention targeting Orai1 may represent a novel therapeutic strategy for inhibiting NP development.
- Orai1 inhibition shows potential for more effective treatment of CRSwNP than current glucocorticoid therapy.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...